Global Market Study on Uveitis Treatment: Asia to Witness fastest Growth by 2020

  • Published On : Apr-2015 |
  • Pages : 92 Pages |
  • Format :

Uveitis, also known as intraocular inflammation, refers to swelling of the middle layer of the eye, commonly known as uvea. Uveitis is common across all age groups, although it is more prevalent in the age group of 20 years - 50 years. Autoimmune disorders, injuries, inflammatory disorders, and surgeries are some common causes of uveitis. Anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis are the common types of uveitis; among these, anterior uveitis is the most common type of uveitis. Uveitis may be acute, chronic, or recurrent. Common symptoms associated with uveitis include blurred vision, eye pain, eye floaters, redness of the eye, and increased sensitivity to light. Treatment for uveitis varies according to the type of uveitis and primarily helps reduce the pain, subdue inflammation, control tissue damage, and restore vision. Anti-inflammatory medication, antibiotics, and immunosuppressive medications are common treatments available for the disease. Corticosteroid and topical cyclosporine medications are most commonly used to treat uveitis. 

North America dominates the global market for uveitis treatment. This is primarily due to rising incidence of uveitis and related disorders, increasing aging population, and growing R&D investments by drug manufacturing companies in the region. Moreover, rising awareness about uveitis is also boosting the growth of the market. The market in Asia is expected to exhibit rapid growth over the next five years. Japan and China are expected to be the fastest growing uveitis treatment markets in the Asian region. Furthermore, the uveitis treatment market in India is also growing due to rising number of uveitis cases and increasing aging population. Some of the key driving forces for uveitis treatment market in emerging countries are the rise in disposable income and a large pool of patients.

In recent times, treatment options for uveitis have increased such as corticosteroids and anti-inflammatory drugs due to rising in number of uveitis cases. The increasing prevalence of eye disorders and rising R&D investments in drug discovery and development are also fueling the growth of the global uveitis treatment market. On the other hand, lack of awareness about eye disorders and poor primary healthcare infrastructure coupled with a lack of health insurance in developing countries are restraining the growth of the uveitis treatment market. Increasing usage of anti-TNF-alpha inhibitor therapy is a recent trend in the global uveitis treatment market. Strong product pipeline and development of molecules from the newer class of uveitis treatment are expected to create opportunities for the growth of the global uveitis treatment market.

This report provides in-depth analysis and estimation of the uveitis treatment market for the period 2014–2020, considering 2013 as the base year for the calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The uveitis treatment market is categorized on the basis of type, treatment, and geography. Based on the type of uveitis, the market comprises anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis. Based on treatment, uveitis treatment includes anti-inflammatory medication, antibiotic/antiviral medication, and immunosuppressive medications. On the basis of geography, the report identifies and analyzes the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW). 

Globally, the uveitis treatment market is witnessing significant growth due to increasing prevalence of uveitis and related complications. Moreover, rising aging population, increasing the prevalence of eye disorders, and growing government initiatives to reduce eye disorders are also driving the growth of the market. However, lack of awareness about eye disorders, poor primary healthcare infrastructure, and lack of health insurance in developing countries inhibits the growth of the market. The global uveitis treatment market is anticipated to grow from an estimated USD 539.0 million in 2014 to USD 822.5 million by 2020 at a CAGR of 7.3% during the forecast period.

North America is the largest market and Asia the fastest growing market for uveitis treatment. In terms of the type of uveitis, anterior uveitis represents the largest growing segment of this market. Anterior uveitis refers to inflammation of the middle layer of the eye, which includes the iris and ciliary body. Anterior uveitis may be acute or chronic in nature. Anterior uveitis is caused mainly due to auto-immune disorders and bacterial, fungal, or viral infections. The anterior uveitis treatment market was estimated at USD 273.1 million in 2014 and is expected to reach USD 416.3 million by 2020, expanding at a CAGR of 7.3 % during the forecast period.

Some of the major players in the uveitis treatment market are pSivida Corp., XOMA Corporation, Alcon, Inc., Allergan, Inc., AbbVie Inc., Enzo Biochem Inc., OphthaliX Inc., Bausch & Lomb Incorporated, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co., Ltd.

Some of the major players in the uveitis treatment market:

  • pSivida Corp.
  • XOMA Corporation.
  • Alcon, Inc.
  • Allergan, Inc.
  • AbbVie Inc.
  • Enzo Biochem Inc.
  • OphthaliX Inc.
  • Bausch & Lomb Incorporated.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Other.

These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Back To Top